A
Avilar Therapeutics
Pioneering the discovery and development of extracellular protein degraders
About Avilar Therapeutics
Avilar Therapeutics is a biotech startup that is pioneering a new approach to drug development by focusing on the degradation of extracellular proteins. The company operates in the pharmaceutical industry, specifically in the area of drug discovery and development.
Traditionally, drug development has focused on intracellular targets, but Avilar is extending this to include extracellular and membrane-bound proteins. This is significant because nearly 40% of human proteins are located outside the cell and many of these play a key role in the development of human diseases. By developing drugs that can degrade these proteins, Avilar aims to create new treatments for a range of serious diseases.
Avilar's business model revolves around the development of a new class of drugs known as ATACs (ASGPR Targeting Chimeras). These are designed to harness the body's natural process for protein degradation. The company has developed a unique, integrated, and modular drug discovery platform that allows for the design and assembly of ATACs targeting a wide array of extracellular proteins.
The company's revenue model is likely to be based on the successful development and commercialization of these new drugs, either through direct sales or through partnerships with larger pharmaceutical companies.
In summary, Avilar is a cutting-edge biotech company that is pushing the boundaries of drug development by targeting extracellular proteins. Its innovative approach could potentially lead to the development of new treatments for a range of serious diseases.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEEDOther financing | Feb 2023 | $15M | $300M | RA Capital Management · Astellas Venture · Sanofi Ventures · Medical Excellence Capital | ↗ |
| SEEDOther financing | Nov 2021 | $60M | $240M | RA Capital Management | ↗ |
Growth signals
Latest recorded traffic for Avilar Therapeutics is 3.1K monthly website visits, up 93.8% over the last three months. Avilar Therapeutics's team declined 4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Avilar Therapeutics in the Watertown ecosystem
The Avilar Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
RA Capital Management
Astellas Venture
Sanofi Ventures
Medical Excellence Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Avilar Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Avilar Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









